Immunome (IMNM) Projected to Post Earnings on Tuesday

Immunome (NASDAQ:IMNM) is projected to release its Q1 2025 earnings data before the market opens on Tuesday, May 13th. Analysts expect Immunome to post earnings of ($0.67) per share and revenue of $0.46 million for the quarter.

Immunome (NASDAQ:IMNM) last released its quarterly earnings results on Wednesday, March 19th. The company reported ($0.84) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.16). Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. The company had revenue of $2.74 million during the quarter, compared to analysts’ expectations of $3.07 million. On average, analysts expect Immunome to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Immunome Price Performance

Shares of Immunome stock opened at $7.46 on Monday. Immunome has a 1 year low of $5.15 and a 1 year high of $16.81. The firm has a market cap of $649.11 million, a PE ratio of -0.92 and a beta of 2.00. The stock has a fifty day moving average price of $7.76 and a 200-day moving average price of $9.94.

Insider Activity

In related news, CTO Philip Tsai purchased 12,300 shares of the firm’s stock in a transaction on Monday, March 24th. The shares were acquired at an average cost of $8.42 per share, with a total value of $103,566.00. Following the purchase, the chief technology officer now directly owns 33,300 shares of the company’s stock, valued at approximately $280,386. This trade represents a 58.57% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Clay B. Siegall purchased 137,100 shares of the firm’s stock in a transaction on Wednesday, March 26th. The stock was bought at an average cost of $7.29 per share, for a total transaction of $999,459.00. Following the completion of the purchase, the chief executive officer now directly owns 806,736 shares in the company, valued at approximately $5,881,105.44. This trade represents a 20.47% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders acquired 156,400 shares of company stock worth $1,160,495. 8.60% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities research analysts recently weighed in on IMNM shares. Guggenheim decreased their price objective on Immunome from $35.00 to $25.00 and set a “buy” rating for the company in a report on Thursday, March 20th. Lake Street Capital started coverage on Immunome in a research note on Wednesday, April 2nd. They issued a “buy” rating and a $23.00 target price for the company. Stephens restated an “overweight” rating and issued a $30.00 target price on shares of Immunome in a research note on Thursday, March 20th. Lifesci Capital started coverage on Immunome in a research note on Tuesday, March 11th. They issued an “outperform” rating and a $20.00 target price for the company. Finally, Wedbush restated an “outperform” rating and issued a $33.00 target price on shares of Immunome in a research note on Thursday, March 20th. Six analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $25.33.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.